Effect of Fenugreek extract (Trigonella foenun-graecum) on early menopausal complications

INTERVENTION: Fenugreek group: two capsules each containing 500 mg Fenugreek extract, daily Hormone therapy group: two capsuls containing estrogen conjugate 0.625mg and medroxy progestron acetat 2.5mg, daily Intervention 1: Fenugreek group: two capsules each containing 500 mg Fenugreek extract, daily. Intervention 2: Hormone therapy group: two capsuls containing estrogen conjugate 0.625mg and medroxy progestron acetat 2.5mg, daily. Intervention 3: Placebo group: two capsules containing lactose, daily. Placebo Placebo group: two capsules containing lactose, daily Treatment ‐ Drugs CONDITION: early menopausal complications. ; Menopausal and female climacteric states Menopausal and female climacteric states PRIMARY OUTCOME: Early menopausal complications. Timepoint: before intervention, fourth and eighth weeks after intervention. Method of measurement: Greene questionnaire. SECONDARY OUTCOME: Side effects. Timepoint: fourth and eighth weeks after intervention. Method of measurement: questionnaire. INCLUSION CRITERIA: INCLUSION CRITERIA: ‐No any menstrual bleeding experience at least during last year. ‐Normal blood pressure. ‐ In evaluation of Green questionnaire, the minimum score is 15. ‐ FSH> 40. Exclusion Criteria: ‐The History of known disease or abnormality (e.g, breast cancer, uterine cancer, endometrial hyperplasia, angina, heart attacks, angioplasty, blood clot, kidney disease, liver disease, thyroid disease, diabetes, migraine headaches). ‐ Abnormal vaginal bleeding ‐ The use of special drugs or treatments like: hormonal therapy, nervous drugs, Corticosteroids drugs and anti‐clot or herbal medicine during the past 6 months. ‐ The use of relaxation techniques during the past 6 months. ‐ Sensitivity to spices and essential oil materials ‐Smoking or drinking Alcohol.